市场调查报告书
商品编码
1497843
药品和医疗设备组合产品市场:按产品、应用和最终用户划分 - 全球预测 2024-2030Drug-Device Combination Products Market by Product (Antimicrobial Catheters, Drug Eluting Stents, Infusion Pumps), Application (Antimicrobial Application, Cancer Treatment, Cardiovascular Disorder), End-user - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年药品和医疗设备组合产品市场规模为1,339.5亿美元,预计2024年将达到1,445.9亿美元,2030年将达到2,310.5亿美元,复合年增长率为8.09%。
药品/医疗设备组合产品是将药品与医疗设备融为一体的独特保健产品。这些产品旨在透过整合药物的药理作用和医疗设备的物理性能来提供协同治疗效果。药物和医疗设备组合产品为未满足的医疗需求或增强现有治疗方法提供了创新的解决方案。药物和医疗设备组合产品将药物和器械结合在一个产品中,与单独施用每种成分相比,可以实现更好的患者治疗效果。这主要是由于药物输送到体内的特定部位,提高了疗效,同时最大限度地减少了副作用和全身毒性。将智慧感测器等先进技术融入这些组合产品中,可以即时监控和控制药物释放曲线,从而促进根据个别患者需求量身定制的个人化医疗方法。此外,糖尿病和心臟病等慢性病的流行增加了对微创和标靶治疗方法的需求。包括美国FDA在内的监管机构不断简化创新组合药物的核准流程,为製造商创造了有利的环境。然而,复杂的法律规范和高成本的研发(R&D)活动成本极大地阻碍了药物-医疗设备组合产品的采用。此外,製造商正在投资研发工作,以满足靶向药物传输系统和生物可吸收植入等领域未满足的临床需求。探索新的药物和设备组合来对抗抗生素抗药性感染疾病和增强癌症治疗有望为药物医疗设备组合产品的开发带来希望。
主要市场统计 | |
---|---|
基准年[2023] | 1339.5亿美元 |
预测年份 [2024] | 1445.9亿美元 |
预测年份 [2030] | 2310.5亿美元 |
复合年增长率(%) | 8.09% |
区域洞察
在美洲,由于慢性病的增加、人口老化、技术进步和有利的报销政策,对组合药物和医疗设备产品的需求正在增加。美国食品药物管理局(FDA) 积极参与支持药物-医疗设备组合产品开发的专利核准和研究倡议。在亚太地区,中国、日本、印度和韩国等国家正专注于寻找具有成本效益的解决方案,以解决许多患有糖尿病和心血管疾病等慢性疾病的患者未得到满足的医疗需求。中国国家监督监督管理局(NMPA)发布新的医疗设备临床评估报告指南,以促进药品医疗设备组合产品的进步。此外,日本的药品和医疗设备法(PMD 法)保证药品、医疗设备和类似产品的品质、有效性和安全性。欧盟国家对生物技术和医疗设备领域的投资迅速增加,与主题和关键字相关的研究活动不断改进。欧洲药品管理局 (EMA) 在评估这些产品的安全性和有效性方面发挥关键作用。领先的公司正在与学术机构合作开发满足特定地区需求的创新解决方案。在中东和非洲地区,多个地区政府正在重点投资医疗基础设施,为组合药物和医疗设备产品的开发创造未来的成长机会。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在製药/医疗设备组合产品市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对製药和医疗设备综合市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在药品和医疗设备综合市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[189 Pages Report] The Drug-Device Combination Products Market size was estimated at USD 133.95 billion in 2023 and expected to reach USD 144.59 billion in 2024, at a CAGR 8.09% to reach USD 231.05 billion by 2030.
A drug-device combination product is a unique class of healthcare products that combines pharmaceuticals and medical devices in a single unit. These products are designed to provide synergistic therapeutic benefits by integrating the pharmacological action of drugs with the physical performance of devices. The drug-device combination product offers innovative solutions for unmet medical needs or enhances existing therapies. Drug-device combination products deliver better patient outcomes compared to each component administered separately by combining drugs and devices into one product. This is primarily due to drug-targeted delivery at specific sites within the body, which increases efficacy while minimizing side effects or systemic toxicity. Incorporating advanced technologies, including smart sensors in these combination products, enables real-time monitoring and control over drug release profiles, which fosters personalized medicine approaches tailored to individual patient needs. Moreover, the prevalence of chronic diseases, including diabetes and heart ailments, has raised the need for minimally invasive and targeted treatment options. Ongoing efforts by regulatory authorities, including the U.S. FDA, to streamline approval processes for innovative combination products provide a favorable environment for manufacturers. However, complex regulatory frameworks and the high cost of research and development (R&D) activities significantly impede the adoption of drug-device combination products. In addition, manufacturers invest in research and development activities to address unmet clinical needs in areas such as targeted drug delivery systems or bioresorbable implants. Exploring new drug-device combinations to fight antibiotic-resistant infections or enhance cancer therapies is expected to create prospects for developing drug-device combination products.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 133.95 billion |
Estimated Year [2024] | USD 144.59 billion |
Forecast Year [2030] | USD 231.05 billion |
CAGR (%) | 8.09% |
Regional Insights
In the Americas, there is a growing need for drug-device combination products due to the increasing prevalence of chronic diseases, the aging population, technological advancements, and favorable reimbursement policies. The U.S. Food and Drug Administration (FDA) has been actively involved in approving patents and supporting research initiatives to develop drug-device combination products. In the Asia-Pacific, countries including China, Japan, India, and South Korea focus on cost-effective solutions to address unmet medical needs for their large patient pool suffering from chronic illnesses such as diabetes or cardiovascular diseases. China's National Medical Products Administration (NMPA) released new guidelines on clinical evaluation reports for medical devices promoting advancements in drug-device combination products. In addition, Japan's Pharmaceuticals and Medical Devices (PMD) Act ensures the quality, efficacy, and safety of pharmaceuticals, medical devices, and similar products. European Union countries have witnessed a surge in investment within biotechnology and medical device sectors, improving research activities on drug-device combination products. The European Medicines Agency (EMA) plays a vital role in evaluating these products' safety and efficacy. Major players collaborate with academic institutions to develop innovative solutions catering to specific regional demands. In the Middle East and Africa region, several regional governments focus on investing in healthcare infrastructure development that provides future growth opportunities for developing drug-device combination products.
Market Insights
The market dynamics represent an ever-changing landscape of the Drug-Device Combination Products Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Drug-Device Combination Products Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Drug-Device Combination Products Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Nemera and Nelson Labs Europe trengthen partnership to offer integrated services to customer
Nemera, a provider of drug delivery device solutions and combination product services, announced strengthening its existing partnership with Nelson Labs Europe, a significant player across the globe in microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. This non-exclusive collaboration allowed Nemera to access extractables & leachables, biocompatibility, microbiology, and chemical testing from Nelson Labs, delivering an integrated service offering to clients for their drug/device combination products and accelerating their market entry. They anticipated a productive collaboration, enhancing their mutual capabilities in providing superior solutions in the medical device and pharmaceutical sectors. [Published On: 2023-03-14]
Kindeva and Meridian Combine: Create Leading Drug-Device Combination Product CDMO
Kindeva Drug Delivery and Meridian Medical Technologies completed their merger, resulting in the formation of a global Contract Development and Manufacturing Organization (CDMO) specializing in drug-device combination products. This merger aimed to expand the range of drug delivery capabilities by leveraging expertise and technology across parenteral, inhalation, transdermal, and intradermal administration routes. [Published On: 2022-12-12]
Terumo Announces Launch of Drug-Device Combination Product Co-Developed with Kyowa Kirin
Terumo Corporation launched G-Lasta Subcutaneous Injection 3.6 mg BodyPod, a novel drug-device combination product created in collaboration with Kyowa Kirin Co., Ltd. The activated device is attached to the patient's body at the clinic during chemotherapy and automatically administers the drug approximately 27 hours later. The introduction of this advanced drug-device combination product streamlines treatment and reduces patient burden associated with post-chemotherapy visits. [Published On: 2022-12-06]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Drug-Device Combination Products Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Drug-Device Combination Products Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Braile Biomedica, Cardinal Health, Inc., CODAN Companies, Cook Group Incorporated, F. Hoffmann-La Roche AG, Fresenius Kabi, ICU Medical, Inc., InfuTronix, InSitu Technologies Inc., Insulet Corporation, JMS North America Corporation, Lepu Medical Technology Company, Medtronic PLC, MicroPort Scientific Corporation, Novartis AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., SOOIL Developments Co., Ltd., Stryker Corporation, Teleflex Incorporated, Terumo Corporation, Viatris Inc., W. L. Gore & Associates Inc., and Zyno Medical.
Market Segmentation & Coverage